Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Eli Lilly said on Thursday it sued the federal Health Resources and Services Administration (HRSA) over allegedly blocking ...

Diane Brady: Leadership Next is powered by the folks at Deloitte who, like me, are exploring the changing roles of business ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in ...

Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...

Conditions are getting a bit more challenging for the drugmaker.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.39% and ...

Eli Lilly (LLY) files lawsuit against U.S. health agency over 340B Program rebates, alleging arbitrary blockage of its cash ...

Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on ...